Single booster dose at 6 months of NVX-CoV2373 increased wild-type neutralizing antibodies more than 4-fold versus primary vaccination series
Sickle Cell Disease Support Corner developed to create a database of individuals with sickle cell disease
The transaction is expected to close in the Q4FY22
He will be responsible for the company's overall strategy and provide the necessary direction and dynamic leadership to R&D, manufacturing, business development, and commercial operations
He will be stationed at the company HQ in Bengaluru, India
Deal for 100 million doses with additional 100 million through 2023
It works as an adjunct to standard care based on robust clinical trials
The Phase III clinical trial for NONS is expected to be completed by Q4 2021.
The first batch will be shipped to the Gamaleya Center for the quality control
Subscribe To Our Newsletter & Stay Updated
